李晓女，上海血液病研究所副所长；上海市血液分会委员；中华血液杂志编委；白血病.淋巴瘤杂志编委；博导，教授，主任医师；多年从事血液学临床工作和基础研究，对各种血液科疾病的诊断和治疗具备丰富经验。近年主要从事血液系统最常见的恶性疾病骨髓增生异常综合征（MDS）的发病机制与临床诊治的研究。曾两次前往美国最大的血液病研究及移植中心进行共同研究及交流。近年来获得多项科研资助，获得上海市科技进步奖2项。以第一作者或通讯作者身份发表SCI论著18篇(总影响因子37.638)。2007/2008年度获上海市三八红旗手称号。曾经和正在进行的重要课题李晓等.三氧化二砷/TRAIL作为MDS治疗新药的临床前期研究(上海市科委重点项目2004)(044119630)李晓等.MDS和急性髓细胞白血病恶性克隆细胞生物学特性研究(上海市科委登山计划2006)(064119635)李晓等参与--骨髓增生异常综合症的规范化诊断与治疗策略（国家“十一五”科技支撑计划2008BAI61B02）李晓等.骨髓增生异常综合征的规范化诊断与分层治疗（申康集团适宜技术应用项目SHDC12010202）已获得奖项李晓等2005年上海市科技进步叁等奖（2005093037）李晓等《骨髓增生异常综合征发病机制和规范诊治的相关研究》2010年上海市科技进步叁等奖（20104387-3-D01）SCI论著（通讯作者）1.HeQi,LiXiao,WuLingyunetal.Expressionoftype1insulin-likegrowthfactorreceptorinmarrownucleatedcellsinmalignanthematologicaldisorders:correlationwithapoptosis.AnnHematol.2006;85(2):95-101.2.WuLingyun,LiXiao,ChangChunkang,etal.DeviationoftypeIandtypeIITcellsanditsnegativeeffectonhematopoiesisinmyelodysplasticsyndrome.IntJLabHematol2008;30(5):390-3993.WuLingyun,LiXiao,SuJiying,etal.Effectoflow-dosecytarabine,homoharringtonineandgranulocytecolony-stimulatingfactorprimingregimenonpatientswithadvancedmyelodysplasticsyndromeoracutemyeloidleukemiatransformedfrommyelodysplasticsyndrome.LeukemiaLymphoma,2009;50(9):1461–14674.XuLi,ChangChunkang,LiXiao,etal.AppropriateTimingofG-CSFUseAfterMobilizationChemotherapySignificantlyIncreasestheYieldofCD341CellsinautoPBSCT.JClinApheresis2009,6;24(6):232-237.5.XuFeng,LiXiao,WuLingyun,etal.Flowcytometricscoringsystem(FCMSS)assisteddiagnosisofmyelodysplasticsyndromes(MDS)andthebiologicalsignificanceofFCMSS-basedimmunophenotypes.BrJHaematol.2010;149(4):587-97.6.ZhangZheng,ZhangQianqiao,HeQi,LiXiao,etal.InvitrodeprivationOfCD8CD57TcellspromotesthemalignantgrowthofbonemarrowColonycellsinpatientswithower-riskmyelodysplasticsyndrome.ExpHematol2010;38:677–6847.HeQi,LiXiao,ZhangZheng,etal.OverexpressionofIGF-IRinMalignantClonalCellsinBoneMarrowofMyelodysplasticSyndromesCancerInvest,2010；28:983–9888.ZhangZheng,XuFeng,LiXiao,etal.RemovalofautologousactivatedCD4-positiveTlymphocytesalsoresultsinincreasedcolony-formingunitsinpatientswithlowandintermediate-1riskmyelodysplasticsyndromes.EurJHaematol,2011；86(47–56)9.XuFeng,LiXiao,WuLingyun，et，al.OverexpressionoftheEZH2,RING1andBMI1genesiscommoninmyelodysplasticsyndromes:relationtoadverseepigeneticalterationandpoorprognosticscoringAnnHematol2011,90:643–65310.WuLingyun,LiXiao,SuJiying,etal.EfficacyandsafetyofCHGregimen(low-dosecytarabine,homoharringtoninewithG-CSFpriming)asinductionchemotherapyforelderlypatientswithhigh-riskMDSorAMLtransformedfromMDSJCancerResClinOncol(2011)137:1563–1569SCI论著（第一作者）11.LiXiao,EileenBryant,H.JoachimDeeg.SimultaneousDemonstrationofClonalChromosomeAbnormalitiesandApoptosisinIndividualMarrowCellsinMyelodysplasticSyndrome.IntJHematol2004;80(2):140—145.12.LiXiao&PuQuan.Megakaryocytopoiesisandapoptosisinpatientswithmyelodysplasticsyndromes.LeukemiaLymphoma2005;46(3):387-391.13.LiXiaoWuLingyun,YingShaoxu,etal.Wilmms’tumorgene(WT1)ispredominantlyexpressedinclonalhematopoieticcellsinmyelodysplasticsyndromes.LeukemiaLymphoma2007;48[3]:601-604.14.LiXiao,WuLingyun,YingShaoxu,etal.Differentiationandhematopoietic-supportofclonalcellsinmyelodysplasticsyndromes.LeukemiaLymphoma2007；48[7]：1353–137115.LiXiao,WuLingyun,YingShaoxu,etal.Clonalityinvestigationofmorphologicallydysplastichematopoieticcellsinmyelodysplasticsyndromemarrows.IntJHematol.2008;87(2):176-83.16.LiXiao,SongLuxi,TaoYing,etal.Diagnosisofunknownnonhematologicaltumorsbybonemarrowbiopsy:aretrospectiveanalysisof10,112samples.JCancerResClinOncol2009;135:687–69317.LiXiao，LiaoQiong，Zhangyanetal.ExperimentalandclinicalcharacteristicsinmyelodysplasticsyndromepatientswithorwithoutHLA-DRI5allele.HematolOncol.2010;28:98-103.18.LiXiao,XuFeng,HeQi,etal.ComparisonofImmunologicalAbnormalitiesofLymphocytesinBoneMarrowinMyelodysplasticSyndrome(MDS)andAplasticAnemia(AA).InterMed201049:1349-1355
